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ABSTRACT
The YO-PRO-1 assay provides a quantitative estimation of P2X7 receptor activation. P2X7 receptor is associated to 
pathological conditions including infectious, inflammatory, neurological, musculoskeletal disorders, pain and cancer. Most 
primary cells and cell lines from diverse origin may be used thanks to the ubiquitous distribution of P2X7 receptor. To 
study the activation of P2X7 receptor by chemicals or biological agents, we established a microplate-based cytometry 
protocol to accurately and rapidly quantify the activation of P2X7 receptor that leads to the formation of large pores in 
cell membranes. The YO-PRO-1 assay is based on the ability of cells to incorporate and bind YO-PRO-1 dye to DNA 
after activation of P2X7 receptor through pore formation. Cells are seeded in 96-well plates and incubated with the 
compound being tested for the appropriate time. The microplate is then incubated for 10 min with YO-PRO-1 staining 
solution. After the 10 min staining time, fluorescence signal is read using a microplate reader in 1 min. This procedure 
is easier and requires less handling steps than flow cytometry. 96-well plate based YO-PRO-1 assay is a reproducible 
and fast method to study both P2X7 receptor activation by toxic agents at subnecrotic concentrations and P2X7 receptor 
inhibition by antagonists.
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BACKGROUND
High throughput screening methods are emerging approaches in 
toxicology, allowing a quick and efficient toxicity evaluation through 
a battery of assays that target cellular processes [1]. These in vitro 
assays are useful for rapidly evaluating a large number of compounds 
and providing insight on potential human health effects [2]. These 
compounds include chemicals, drugs, plant extracts, environmental 
substances, formulations…
P2X7 receptor, originally classified as P2Z receptor, has attracted 
more and more interest from the biomedical research community over 
the years, as shown in Figure 1, which has been generated by The 
“Results by year” PubMed timeline tool. Indeed, P2X7 receptor was 
discovered in 1996, which resulted in nine publications that year; al-
most twenty years later, more than 2240 publications are available on 
PubMed database, with 252 papers published in 2015.
P2X7 receptor is expressed by virtually all types of cells [3-5], 
including zebrafish, fish and frog cells [6-8]. This receptor belongs 
to P2X family ionotropic receptor binding ATP [9]. P2X7 receptors 
require higher concentrations of ATP for activation compared with 
other P2X receptors, and 2,3-O-(4-benzoylbenzoyl)-ATP (BzATP) 
is approximately 30-fold more potent than ATP in the human and rat 
[9,10]. BzATP is extensively used in research as the agonist of choice 
for P2X7 receptor [11-13]. Brief stimulation of P2X7 receptor leads 
to an increase in intracellular calcium influx whereas repeated or pro-
longed (> 15 min) stimulation of P2X7 receptor induces the formation 
of a non-selective pore. This pore allows the entry of solutes up to 900 
Da in size, which eventually leads to membrane blebbing, release of 
cytokines and activation of caspases ultimately leading to cell death 
[14-19]. P2X7 receptors activation is responsible for a large number of 
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biological processes; consequently, P2X7 receptor has been associated to 
pathological conditions including infectious, inflammatory, autoimmune, 
neurological, musculoskeletal disorders, pain and, cancer [12,20-27]. 
The role of P2X7 receptor in numerous pathologic conditions makes 
it a major therapeutic target, both in studies aiming at inhibiting P2X7 
receptor and in studies aiming at activating P2X7 receptor (during the 
development of anticancer strategies).
Figure 1. Number of P2X7-related publications per year (source: 
PubMed, keyword: P2X7).
Development of the method
Through the formation of P2X7 pore, the cells become permeable 
for cationic dyes such as quinolinium,4-[(3-methyl-2(3H)-benzoxaz-
olylidene)methyl]-1[3-(triethylammonio)propyl]-, diiodide (YO-PRO-1, 
629 Daltons for the di-iodide salt; 375 Daltons for free base) [28,29]. 
YO-PRO-1 is a cell membrane-impermeant cation whose fluorescence 
increases upon binding nucleic acids [30] and thus represents an excellent 
probe for detecting permeability changes in P2X7 receptor (Fig. 2).
Originally, YO-PRO-1 signal was observed under fluorescence 
microscopy [9,31] then quantified using microplate cytometry [32,33] 
or flow cytometry [34]. The first studies looking at P2X7 activation 
through YO-PRO-1 uptake used fluorescence microplate readers with 
filter detection systems; we were among the first to use a monochro-
mator-based system [35-43]. Excitation and emission wavelengths for 
YO-PRO-1 are very close, 491 nm and 509 nm, respectively (Fig. 3).
With monochromator-based readers, the wavelengths to be measured 
are generally available in 1-nm increments. This is very useful with 
fluorescent tags that have close excitation and emission wavelengths to 
avoid wavelengths overlap and then reduce background fluorescence 
and increase sensitivity and specificity of the tag.
Our 96-well plate-based method for the evaluation of P2X7 re-
ceptor activation using YO-PRO-1 fluorescent dye was developed for 
adherent living cells so the whole assay, from the incubation with the 
compounds being evaluated to the quantification of YO-PRO-1 signal, 
can be performed in the same 96-well plate. Minimizing sample handling 
procedures such as centrifugation and pipetting steps limits the risk to 
affect the levels of apoptotic body formation. This microtiter plate-
based assay offers a simple, reproducible, fast, relatively inexpensive, 
accurate cell-based method for high throughput screening of numerous 
compounds (such as drugs, chemicals, pollutants, xenobiotics…) in their 
ability to activate P2X7 receptor and therefore cell death [36,37,44,45]. 
It can also be used to study physiopathologic mechanisms implicated 
in degenerative diseases. Indeed, we previously used this technique to 
highlight the role of P2X7 receptor activation in age-related macular 
degeneration [2,46]. Retinal cells (human retinal pigment epithelial 
ARPE-19 cell line and human retinal Müller glial MIO-M1 cell line) 
were incubated with amyloid β peptide or oxysterols, involved in 
degenerative diseases such as Alzheimer and age-related macular de-
generation, then the YO-PRO-1 assay that we describe here was used to 
study P2X7 receptor activation. This assay allowed us to conclude that 
P2X7 receptor could be an important target to develop new treatments 
for age-related macular degeneration.
Figure 2. Schematic representation of YO-PRO-1 uptake after P2X7 
receptor activation.
Figure 3. Fluorescence spectra of YO-PRO-1. Reprinted from Thermo 
Fisher Scientific website, retrieved September 15, 2016 from https://www.
thermofisher.com/order/catalog/product/Y3603.
Comparison with other techniques
Flow cytometry is not widely used as a screening tool due to the 
limitations in handling large numbers of samples and may not be as 
adapted as microplate cytometry for high throughput screening. Mi-
croplate cytometry is the quantitative analysis of cells in a microplate 
using a microplate reader. The use of microplates in cytometry provides 
opportunities to screen large numbers of samples.
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Experimental design
This protocol provides instructions for performing a cell-based 
procedure that quantifies the activation of P2X7 receptor directly in 
96-well microplate. The procedure can be divided into three main parts: 
preparation of samples (Steps 1–15), preparation of stains and sample 
staining (Steps 16–17); and data acquisition by microplate cytometry 
and data analysis (Steps 18–19).
Preparation of samples
Disruption of cell membrane integrity, a feature of necrosis, can lead 
to YO-PRO-1 entry in cells through necrotic pores [47]. In that case, 
increase in YO-PRO-1 uptake is not due to P2X7 receptor activation 
but to altered membrane integrity occurring during necrosis. To avoid 
misinterpretation of the results, YO-PRO-1 fluorescence signal has 
to be monitored on cells with preserved membrane integrity where-
in YO-PRO-1 can only enter through activated P2X7 receptor [48]. 
Neutral red uptake assay for the estimation of cell viability through 
measurement of membrane integrity is highly recommended [49], but 
other cell viability assays can be used such as the Alamar Blue assay 
[50] or the MTT assay [51].
We developed the procedure for adherent cell lines (epithelial cells, 
macrophages, glial cells…) but it can be adapted to any primary cells, 
and also to suspension and non-adhesive cells (leukocytes, monocytes…) 
on condition that a centrifuge equipped with standard microplate holder 
is used. Cell lines obtained from various immortalization processes 
were tested: spontaneously immortalized cells, SV40 large T-antigen 
immortalized cells, and cancer cells. As YO-PRO-1 is light sensitive, 
clear bottom black 96-well microplates should be preferred. The cells 
are plated into 96-well microplates; it is worth noting that seeding den-
sities are chosen to reach subconfluence in 24 h. The culture medium in 
which the cells are seeded is growth medium (generally supplemented 
with 10% FCS). The cells are incubated with the compounds suspected 
to activate P2X7 receptor directly in the microplate. The choice of the 
solution in which the compounds are diluted depends on the incubation 
time: for short incubation times (from 15 min to 1 h), the compounds 
can be diluted in phosphate buffer saline but for longer incubation times 
(superior to 1 hour), the compounds have to be diluted in maintenance 
medium (no more than 5% FCS, 2.5% is a good option for most cases) 
to avoid cell proliferation and reduction in sensitivity of chemicals with 
high protein affinity in 10% FCS.
Positive controls should be included in the assay to check the ability 
of agonists to activate P2X7 receptor in the chosen cell model. ATP 
(millimolar concentration) and BzATP (micromolar concentration) are 
the agonists of choice for YO-PRO-1 uptake studies.
If the assay is run on nonadherent cells, the microplate has to be 
centrifuged before any removal of cell supernatants. It should be noted 
that centrifugation will introduce a stage of sample handling that could 
influence the cell viability. Therefore, high centrifugation speed should 
be avoided (maximum 1800 rpm).
Preparation of staining solution and sample staining
As divalent cations alter the affinity of ATP binding to the P2X7 
receptor [29,38,52], it is of high importance to dilute YO-PRO-1 stock 
solution in phosphate buffer saline without calcium nor magnesium. 
After removal of the compound being evaluated, the cells are incubated 
with YO-PRO-1 dye directly in the microplate for only 10 min. It is 
noteworthy that neither fixation nor permeabilization are needed.
Data acquisition by microplate cytometry
In the data acquisition software of the microplate reader, YO-PRO-1 
excitation and emission wavelengths have to be specifically selected 
(491 nm, 509 nm) with the narrowest bandwidths. To ensure optimal 
fluorescence signal recording, it is crucial during data acquisition to let 
the microplate reader determine the optimal gain setting by selecting 
an automatic gain adjustment option. YO-PRO-1 fluorescence signal is 
monitored directly in the microplate without any washing step.
After YO-PRO-1 fluorescence signal quantitation, the cells can be 
observed by live-cell fluorescence microcopy technique and pictures 
can be taken to illustrate YO-PRO-1 uptake.
MATERIALS
The indicated suppliers listed below can be substituted with appro-
priate alternatives.
Reagents
 9 Cultured human corneal epithelial SV40 large T-antigen im-
mortalized HCE cell line (Human Corneal Epithelial cells, 
Riken Cell Bank (RCB), cat. #1384)
 9 Cultured human retinal epithelial spontaneously immortalized 
ARPE-19 cell line (ATCC, cat. #CRL2302)
 9 Cultured human cutaneous epithelial spontaneously immortal-
ized HaCaT cell line (Cell Lines Service, Batch #300493–2417)
 9 Cultured human placental trophoblast-derived choriocarcinoma 
JEG-3 cell line (ATCC, cat. #HTB-36)
We have also used this procedure on various primary cells and 
animal cell lines.
NOTE: The cell lines used in your research should be regularly 
checked to ensure that they are authentic and not infected 
with Mycoplasma. Mycoplasma contamination can affect the 
levels of YO-PRO-1 staining.
 9 Dulbecco’s Modified Eagle’s Medium (DMEM, Eurobio, cat. 
#CM1DME6001)
 9 HAM F12 medium (Eurobio, cat. #CM1H1200K)
 9 Minimum Essential Media (MEM, Eurobio, cat. #CM-
1MEM1001)
 9 Penicillin-streptomycin mixture (Eurobio, cat. #CAB-
PES01-0U)
 9 Glutamin (Eurobio, cat. #CSTGLU00-0U)
 9 FCS (Eurobio, cat. #CVFSVF00-01)
 9 PBS without Ca2+ and Mg2+ (Eurobio, cat. #CS1PBS01K)
 9 Trypsin-EDTA (Eurobio, cat. #CEZTDA00-OU)
 9 YO-PRO-1 iodide (Thermofisher Scientific, cat. #Y3603)
CAUTION: YO-PRO-1 may cause skin, eye and respiratory 
corrosion/irritation and exerts specific target organ systemic 
toxicity. Avoid contact with skin and eyes and always wear 
gloves when preparing and using YO-PRO-1.
Equipment
 9 Tissue culture incubator, humidified, 5% CO2/95% air, with 
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temperature adjustable to the requirements of the cells (Binder 
C150)
 9 Microscope (DMIRB LEICA)
 9 Centrifuge tubes, 50 ml (Corning, cat. #430291)
 9 Centrifuge (Thermofisher Scientific-Jouan B4i) equipped with 
standard microplates holders if nonadherent cells are used
 9 Thoma cell counting chamber (or any cell counter)
 9 Black flat- and clear-bottomed 96-well tissue culture micro-
plates (Corning, cat. #3603)
 9 8-well multichannel electronic pipette 50–1200 µl (Picus, 
Sartorius) and tips
 9 Fluorescence microplate reader using dual monochromators 
(Safire, Tecan) with acquisition software (XFluor 4, Tecan)
 9 Optional: inverted fluorescence microscope
Reagent setup
Growth culture medium for HaCaT cells Supplement DMEM medium 
with 10% (v/v) FCS, 2 mM glutamin and 50 IU/ml penicillin-strepto-
mycin mixture. This medium can be stored at 4°C for up to 2 months.
Growth culture medium for HCE and ARPE-19 cells Mix DMEM 
and HAM F12 mediums with 1:1 ratio. Supplement the mixture medium 
with 10% (v/v) FCS, 2 mM glutamin and 50 IU/ml penicillin-strepto-
mycin mixture. This medium can be stored at 4°C for up to 2 months.
Growth culture medium for JEG-3 cells Supplement MEM medium 
with 10% (v/v) FCS, 2 mM glutamin and 50 IU/ml penicillin-strepto-
mycin mixture. This medium can be stored at 4°C for up to 2 months.
Maintenance medium Supplement DMEM medium, DMEM/HAM 
F12 mixture, or MEM with 2.5% (v/v) FCS, 2 mM glutamin and 50 
IU/ml penicillin-streptomycin mixture. This medium can be stored at 
4°C for up to 2 months.
Test solutions Test solutions must be prepared immediately before 
use, unless stability data demonstrate the acceptability of storage. The 
compounds suspected to activate P2X7 receptor have to be diluted in 
maintenance medium (for long incubation time) or in PBS without Ca2+ 
and Mg2+ (for short incubation time).
YO-PRO-1 staining solution Dilute YO-PRO-1 iodide stock solution 
to 2 µM in PBS.
CRITICAL STEP: The staining solution should be freshly 
made no more than 30 min before the cell staining step, and 
it should be kept in the dark at room temperature (20°C).
Equipment setup
Using the fluorescence microplate reader software, select when 
possible the following measurement parameters:
 9 96-well microplate (select the brand you have purchased, for 
example Corning)
 9 Excitation wavelength: 491 nm with the narrowest bandwidth 
(5 nm)
 9 Emission wavelength: 509 nm with the narrowest bandwidth 
(5 nm)
 9 Optimal gain
 9 Bottom reading
 9 Either reading with microplate cover or reading without mi-
croplate cover can be performed
PROCEDURE
Cell seeding • TIMING 45 min
1. Discard the growth culture medium the cells are growing in and rinse the cells by gentle agitation in PBS 
without Ca2+ and Mg2+ to remove any remaining serum, which might inhibit the action of the trypsin. 10 ml 
is enough for a 75-cm2 flask. Discard the PBS.
CRITICAL STEP: The procedures on the first day (steps 1–10) should be carried out under aseptic conditions 
and in the sterile environment of a laminar flow cabinet.
2. Add ~3 ml trypsin–EDTA solution at the culture temperature to the monolayer and incubate the flask in the 
tissue culture incubator for 2–3 min.
3. Lightly tap the flask to detach the cells and add growth culture medium (twice that of the trypsin volume to 
neutralize trypsin).
4. Transfer the suspension to a cell culture-treated tube and centrifuge at 1800 rpm for 3 min to eliminate the 
supernatant containing trypsin and resuspend the cells in fresh growth culture medium (~10 ml).
5. Count a sample of the cell suspension using a Thoma cell counting chamber (or a cell counter).
6. Dilute the cells with growth culture medium, preparing at least 15 ml per microplate of the cell suspension 
of an adequate cell density according to the cell type and the design of the study. Approximately 6 × 104 
cells/ml is adequate for most cell lines to obtain subconfluent cells in 24 h.
CRITICAL STEP: If nonadherent cells are used, a 5-min centrifugation step before each change of reagents is 
necessary.
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7. Using a multichannel electronic pipette, dispense 200 µl of PBS only into the peripheral wells of a 96-well 
tissue culture microplate because evaporation mainly affects the peripheral wells of a plate (edge effect).
8. Agitate gently the cell suspension and place it in a sterile reservoir.
CRITICAL STEP: Ensure a uniform cell suspension by pipetting up and down several times.
9. Dispense 200 µl of the cell suspension into the 60 remaining wells of the microplate.
10. Cover the plate and incubate the cells in the tissue culture incubator (37°C, 5% CO2, humidified atmosphere) 
for 24 h. This incubation period allows for cell adherence and for exponential growth.
Cell incubation with the compounds being evaluated • TIMING 30 min
11. Check the correct growth of the cells under a microscope.
12. Prepare test solutions immediately before use to avoid problems of stability and precipitation of the com-
pounds or medium proteins.
CRITICAL STEP: The procedures on the second day (steps 11–15) should be carried out under aseptic conditions 
and in the sterile environment of a laminar flow cabinet if the incubation time with the compounds being evaluated 
is long (above 24 h).
13. Discard the culture medium from the microplate and rinse the cells with PBS without Ca2+ and Mg2+.
14. Add 200 µl of solutions in the wells where cells were seeded. There are several possible designs according 
to the study, but a very common format is: B2-G2 negative control with maintenance medium or PBS (de-
pending on the solution being used for compounds dilution), B3-G3 positive control (ATP and/or BzATP), 
B4-G4 solvent control if needed, B5-G11 compounds being evaluated at different concentrations (at least 
three wells per concentration, so maximum 14 samples).
CRITICAL STEP: For long incubation times (above 24 h), the culture medium used for the dilution of the com-
pounds being evaluated should contain less FCS than the growth culture medium to both minimize cell proliferation 
and the binding of the compounds to proteins, but also to assure cell survival within the exposure period.
15. Incubate the microplate at appropriate conditions (room temperature or 37°C, short or long incubation times).
YO-PRO-1 uptake assay • TIMING 15 min
16. After incubation with the compounds being evaluated for P2X7 receptor activation, discard the supernatant 
and rinse the cells with PBS without Ca2+ and Mg2+.
CRITICAL STEP: Before performing the YO-PRO-1 uptake assay, check that cell viability is not altered by the 
products being studied with the neutral red assay for example, as described by Repetto et al. [49] If the products 
being studied statistically decreased cell viability, then lower concentrations should be tested to identify subcytotoxic 
concentrations for the YO-PRO-1 experiment.
17. Add 200 μl of YO-PRO-1 staining solution to all cell-seeded wells and incubate at room temperature for 10 
min in the dark.
CRITICAL STEP: It is important to keep the microplate in the dark during incubation with YO-PRO-1. Aluminum 
foil can be used to entirely recover the microplate.
Data acquisition by microplate cytometry • TIMING 1 min
18. Measure the fluorescence signal in a fluorescence microplate reader with YO-PRO-1 measurement param-
eters (see Equipment setup).
19. Analyze data using the software provided with the microplate reader to calculate mean fluorescence intensity, 
standard deviation and draw graphs.
20. It is recommended to repeat the experiment at least three different times.
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Optional: Observation by live-cell fluorescence microscopy • TIMING 30 min
21. Discard the YO-PRO-1 solution
22. Observe YO-PRO-1 fluorescence using live-cell fluorescence microcopy and take pictures to illustrate YO-
PRO-1 uptake.
ANTICIPATED RESULTS
The procedure describes a model system using the human epithelial 
HCE, ARPE-19, HaCaT, JEG-3 cells, and P2X7 receptor agonists, ATP 
and BzATP, to exemplify this approach for evaluating P2X7 receptor 
activation. In the four cell lines, neither ATP nor BzATP caused decrease 
in cell viability. To analyze YO-PRO-1 fluorescence data, we suggest to 
calculate mean fluorescence intensity of negative control (n = 6 for one 
experiment), then to normalize each fluorescence raw data (negative 
control, positive control, solvent, and compounds being evaluated) to 
the fluorescence mean of negative control (divide all individual value 
for each sample by the mean value of negative control). Then, means 
and standard deviations of each sample are calculated from normalized 
data. In our case, statistical analysis was performed using GraphPad 
Prism 6 software to run a one-way ANOVA follower by Dunnett’s test 
with risk α at 5%.
Figure 4 shows the results obtained with human corneal, cutaneous, 
retinal and placental cell lines. The cells were incubated with ATP or 
BzATP for 15 min and the assay was then carried out. An increase in 
YO-PRO-1 uptake is observed with both ATP and BzATP.
In Figure 4A, when HCE cells are incubated with ATP 3 mM and 
BzATP 150 µM, we respectively observe a 1.22-fold and a 1.38-fold 
increase in YO-PRO-1 uptake, compared to negative control (arbitrary 
fixed to 1). To illustrate these data, the cells were observed under fluo-
rescence microscopy and representative pictures were taken (see Fig. 
S1). In Figure 4B, ATP 10 mM and BzATP 500 µM respectively induce 
a 1.45-fold and a 1.65-fold increase in YO-PRO-1 uptake, compared 
to negative control, in HaCaT cells. In Figure 4C, a 1.45-fold increase 
in YO-PRO-1 uptake after ATP 10 mM and a 1.65-fold increase after 
BzATP 500 µM are observed in ARPE-19 cells. In Figure 4D, ATP 0.1 
mM induced a 1.45-fold increase in YO-PRO-1 in JEG-3 cells compared 
to negative control, and BzATP 300µM induced a 1.70-fold increase. 
It is important to know that some compounds may induce higher YO-
PRO-1 intake than ATP and BzATP do [37,46].
The assay has to be performed on cells expressing P2X7 receptor; 
otherwise, negative results could be misinterpreted and the conclusions 
of YO-PRO-1 uptake assay would be false.
Figure 4. YO-PRO-1 uptake assay on human corneal cells (A, HCE), human cutaneous cells (B, HaCaT), human retinal cells (C, ARPE-19) and 
human placental cells (D, JEG-3). ATP and BzATP were incubated for 15 min then the assay was carried out. Graphs show the fluorescence mean 
with the standard deviations. *P < 0.05; **P < 0.01; ****P < 0.0001 compared to negative control.
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In conclusion, the procedure we propose here using microplate 
cytofluorometry is easier and requires less handling steps than other 
fluorescence techniques. 96-well plate based YO-PRO-1 assay is a 
reproducible and fast method to study both P2X7 receptor activation 
by toxic agents at subnecrotic concentrations and P2X7 receptor inhi-
bition by antagonists.
TROUBLESHOOTING
Troubleshooting advice can be found in Table 1.
Table 1. Troubleshooting table. 
Problem Possible reason Solution
Low YO-
PRO-1 signal 
in positive 
control
Low cell density Increase cell density
YO-PRO-1 exposure 
to light
Use aluminum foils to protect 
the microplate and the recipi-
ent where YO-PRO-1 staining 
solution is prepared
Alteration of YO-PRO-1 
dye
Avoid freeze/thaw cycles by 
aliquoting stock solution
Cell of interest may not 
express P2X7 receptor
Check P2X7 expression using 
immunolabelling
Staining solution was 
prepared too much in 
advance
Prepare YO-PRO-1 staining 
solution immediately before 
cell staining
High YO-
PRO-1 signal 
in negative 
control
Wide bandwidth Reduce bandwidth
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Supplementary information
Figure S1. Fluorescence microscopy observations of YO-PRO-1 
uptake assay on HCE cells: Negative control (A), ATP 3mM (B) and 
BzATP 150µM (C) related to Figure 4A. ATP and BzATP were incubat-
ed for 15 min then the assay was carried out. The cells were observed 
under fluorescence microscopy (Leica DMIRB, Wetzlar, Germany) 
and representative pictures were taken using Nikon Coolpix camera 
(Nikon, Shinjuku, Japan).
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